MCID: PTT009
MIFTS: 54

Pituitary Gland Disease

Categories: Endocrine diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pituitary Gland Disease

MalaCards integrated aliases for Pituitary Gland Disease:

Name: Pituitary Gland Disease 12 15 17
Pituitary Dysfunction 54 71
Pituitary Diseases 54 71
Pituitary Deficiency 58
Pituitary Disorders 42
Pituitary Disease 12

Classifications:

Orphanet: 58  
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:53
ICD9CM 34 253.1
ICD10 32 E23.6 E23.7
ICD10 via Orphanet 33 E23.0
UMLS via Orphanet 72 C0020635
Orphanet 58 ORPHA101957
UMLS 71 C0029493 C0032002 C0281947

Summaries for Pituitary Gland Disease

MedlinePlus : 42 Your pituitary gland is a pea-sized gland at the base of your brain. The pituitary is the "master control gland" - it makes hormones that affect growth and the functions of other glands in the body. With pituitary disorders, you often have too much or too little of one of your hormones. Injuries can cause pituitary disorders, but the most common cause is a pituitary tumor.

MalaCards based summary : Pituitary Gland Disease, also known as pituitary dysfunction, is related to congenital hypopituitarism and hypothyroidism, central, with testicular enlargement, and has symptoms including seizures, tremor and back pain. An important gene associated with Pituitary Gland Disease is PRL (Prolactin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Aldosterone synthesis and secretion. The drugs Dexmedetomidine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include pituitary gland, pituitary and brain, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Disease Ontology : 12 An endocrine system disease that is located in the pituitary gland.

Wikipedia : 74 In vertebrate anatomy, the pituitary gland, or hypophysis, is an endocrine gland, about the size of a... more...

Related Diseases for Pituitary Gland Disease

Diseases related to Pituitary Gland Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 congenital hypopituitarism 33.0 PROP1 HESX1 GHRH
2 hypothyroidism, central, with testicular enlargement 32.5 TRH PROP1 PRL POU1F1 LHX3
3 septooptic dysplasia 31.7 TRH PROP1 PRL POU1F1 POMC LHX3
4 hypopituitarism 31.7 TRH RNU4ATAC PROP1 PRL POU1F1 POMC
5 pituitary tumors 31.0 SST PROP1 PRL POMC MEN1 IGF1
6 dwarfism 30.9 RNU4ATAC GHRH GH1
7 hypoglycemia 30.8 SST PRL POMC INS IGF1 GHRH
8 hypogonadism 30.8 PROP1 PRL INS IGF1 GNRH1
9 secondary adrenal insufficiency 30.7 INS IGF1 AVP
10 adenoma 30.7 TRH SST PRL POU1F1 POMC MEN1
11 diabetes insipidus 30.7 PRL POMC INS GH1 CRH AVP
12 chromophobe adenoma 30.7 TRH PRL POMC GH1
13 insulin-like growth factor i 30.7 PRL INS IGF1 GHRH GH1
14 hyperprolactinemia 30.7 TRH SST PRL POMC INS IGF1
15 acromegaly 30.7 TRH SST PRL POMC MEN1 INS
16 lymphocytic hypophysitis 30.7 POMC GH1
17 holoprosencephaly 30.6 PROP1 POU1F1 LHX3 HESX1
18 sexual disorder 30.6 PRL POMC INS IGF1 GNRH1
19 hypothyroidism, congenital, nongoitrous, 4 30.6 PROP1 PRL POU1F1 POMC GH1
20 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 30.6 GHRH GH1
21 non-functioning pituitary adenoma 30.5 SST GH1
22 intracranial hypertension, idiopathic 30.5 POMC IGF1 GH1
23 polycystic ovary syndrome 30.5 PRL POMC INS IGF1 GNRH1 GH1
24 central precocious puberty 30.5 IGF1 GNRH1 GH1
25 adrenal adenoma 30.5 POMC MEN1 INS CRH
26 glucose intolerance 30.5 POMC INS IGF1 GH1
27 fibrous dysplasia/mccune-albright syndrome 30.5 PRL GH1
28 galactorrhea 30.4 PRL IGF1
29 gynecomastia 30.4 PRL POMC GNRH1
30 pituitary hormone deficiency, combined, 1 30.4 POU1F1 LHX3 HESX1
31 adenohypophysitis 30.4 TRH PRL POMC GH1
32 multiple endocrine neoplasia, type i 30.4 SST PRL POMC MEN1 INS GHRH
33 acth-secreting pituitary adenoma 30.4 SST PRL POMC MIR93 MEN1 CRH
34 hypogonadotropic hypogonadism 30.4 PROP1 PRL INS HESX1 GNRH1
35 hyperthyroidism 30.4 TRH SST PRL POMC INS IGF1
36 substance abuse 30.4 PRL POMC INS CRH
37 anorexia nervosa 30.4 PRL POMC INS IGF1 GHRH GH1
38 pituitary stalk interruption syndrome 30.4 PRL POU1F1 HESX1 GH1
39 cranial nerve palsy 30.4 PRL POMC AVP
40 hypothalamic obesity 30.4 INS IGF1 GHRH
41 graves disease 1 30.4 TRH POMC INS
42 amenorrhea 30.4 TRH PRL POMC INS IGF1 GNRH1
43 hormone producing pituitary cancer 30.4 SST PRL POMC MEN1 IGF1 GHRH
44 pituitary adenoma, prolactin-secreting 30.3 TRH SST PRL POU1F1 POMC MIR93
45 fibromyalgia 30.3 PRL POMC IGF1 CRH
46 craniopharyngioma 30.3 TRH PROP1 PRL POU1F1 INS IGF1
47 meningioma, familial 30.3 SST PRL POMC MEN1 IGF1
48 inappropriate adh syndrome 30.3 POMC CRH AVP
49 isolated growth hormone deficiency 30.3 RNU4ATAC PROP1 POU1F1 POMC LHX3 IGF1
50 sleep disorder 30.3 PRL POMC INS IGF1

Graphical network of the top 20 diseases related to Pituitary Gland Disease:



Diseases related to Pituitary Gland Disease

Symptoms & Phenotypes for Pituitary Gland Disease

UMLS symptoms related to Pituitary Gland Disease:


seizures, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Pituitary Gland Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 AIP CRH GHRH GNRH1 HESX1 IGF1
2 growth/size/body region MP:0005378 10.28 AIP CRH GHRH GNRH1 HESX1 IGF1
3 homeostasis/metabolism MP:0005376 10.28 AIP AVP CRH GHRH GNRH1 IGF1
4 nervous system MP:0003631 10.13 AVP CRH GHRH GNRH1 HESX1 IGF1
5 immune system MP:0005387 10.11 AVP CRH GHRH GNRH1 IGF1 INS
6 liver/biliary system MP:0005370 9.92 AIP CRH GHRH GNRH1 INS MEN1
7 renal/urinary system MP:0005367 9.7 AVP CRH GNRH1 IGF1 INS POMC
8 reproductive system MP:0005389 9.61 GHRH GNRH1 IGF1 INS LHX3 MEN1
9 skeleton MP:0005390 9.28 AVP CRH GHRH GNRH1 IGF1 INS

Drugs & Therapeutics for Pituitary Gland Disease

Drugs for Pituitary Gland Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
4
Acetaminophen Approved Phase 4 103-90-2 1983
5
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
6
Ibuprofen Approved Phase 4 15687-27-1 3672
7
Morphine Approved, Investigational Phase 4 57-27-2 5288826
8
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
12
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
leucovorin Approved Phase 4 58-05-9 6006 143
16
Cefazolin Approved Phase 4 25953-19-9 656510 33255
17
Cefdinir Approved Phase 4 91832-40-5 6915944
18
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
19
Sulfamethoxazole Approved Phase 4 723-46-6 5329
20
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
21
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
22
Pasireotide Approved Phase 4 396091-73-9 9941444
23
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
24
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
25
Cabergoline Approved Phase 4 81409-90-7 54746
26
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
29 Anesthetics Phase 4
30 Adrenergic alpha-Agonists Phase 4
31 Adrenergic Agents Phase 4
32 Hypnotics and Sedatives Phase 4
33 Adrenergic Agonists Phase 4
34 Hydrocortisone-17-butyrate Phase 4
35 Neuroprotective Agents Phase 4
36 Analgesics Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Narcotics Phase 4
39 Analgesics, Opioid Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4
42 Antirheumatic Agents Phase 4
43 Immunologic Factors Phase 4
44 Methylprednisolone Acetate Phase 4
45 Immunosuppressive Agents Phase 4
46 Triamcinolone diacetate Phase 4
47 triamcinolone acetonide Phase 4
48 Triamcinolone hexacetonide Phase 4
49 Protective Agents Phase 4
50 Vitamin B Complex Phase 4

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach Unknown status NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors Unknown status NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
4 Effect of Modified-release Compared to Conventional Hydrocortisone on Fatigue, Measured by Ecological Momentary Assessments; a Pilot Study. Unknown status NCT02282150 Phase 4 Hydrocortisone;Plenadren
5 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
6 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
7 Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
8 A Phase IV Open-label Study of Predictive Markers in Growth Hormone Deficient Pre-pubertal Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
9 Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy Completed NCT01652495 Phase 4 methylprednisolone acetate;Triamcinolone Acetonide
10 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
11 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
12 Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles Unknown status NCT03044756 Phase 2, Phase 3 Omit Citrotide 0.25 dose on the day of triggering of ovulation
13 The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration Unknown status NCT00386022 Phase 2, Phase 3 GnRH;NAL-GLU GnRH antagonist;Estrogen patch
14 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency. Completed NCT00294619 Phase 3 growth hormone
15 A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency Completed NCT00596037 Phase 3 Growth hormone - LB03002
16 Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa Completed NCT01653743 Phase 3 MSJ-0011;urinary hCG (u-hCG);Follitropin alpha
17 Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study Completed NCT01185782 Phase 3 Gonalef® (Follitropin alfa);Purified pituitary gonadotropin (Fertinorm-P®)
18 Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
19 A Prospective, Single-Center, Open-Label, Randomized Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Regimens of Oral Contraceptive Pills Completed NCT00117273 Phase 3 Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)];Seasonique (LNG/EE and EE);Portia (LNG/EE)
20 Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions Completed NCT00306683 Phase 3 DIAZOXIDE
21 fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD Completed NCT03305016 Phase 3 TransCon hGH
22 A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD) Completed NCT02781727 Phase 3 Once weekly subcutaneous injection of TransCon hGH;Once daily subcutaneous injection of Genotropin
23 Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial Completed NCT03271918 Phase 3 Cabergoline
24 A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly Ardana (ARD)-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy Completed NCT00448747 Phase 3 AEZS-130 (formerly ARD-07);L-ARG+GHRH
25 Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
26 An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Recruiting NCT03882034 Phase 3 Pegvisomant
27 The Efficacy, Safety and Tolerability of TransCon hGH Administered Weekly Versus Daily hGH in Prepubertal Children With Growth Hormone Deficiency: a Randomized, Open-lable, Active-controlled, Parallel-group Study in China Recruiting NCT04326374 Phase 3 TransCon hGH;daily hGH
28 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial Recruiting NCT02288962 Phase 3 cabergoline
29 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
30 enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial Active, not recruiting NCT03344458 Phase 3 TransCon hGH
31 Radiotherapy Plus Concomitant Temozolomide for Refractory Pituitary Adenomas,A Randomized,Double-blind, Placebo-controlled Phase II Trial Not yet recruiting NCT04244708 Phase 2, Phase 3 Radiotherapy plus temozolomide
32 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
33 A Multicentre, Prospective, Open Study to Describe the Effects of rhLH Supplement in Women With Hyporesponse to rFSH After Pituitary Downregulation. Unknown status NCT01029470 Phase 2 Luveris
34 An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma Completed NCT01283542 Phase 2 Pasireotide LAR
35 A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
36 A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism Completed NCT01673646 Phase 2 Pasireotide LAR
37 Study of Thyrotropin Releasing Hormone in Patients With Thyroid or Pituitary Abnormalities Completed NCT00054756 Phase 2 TRH (Thyrotropin Releasing Hormone)
38 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
39 Interstitial Radioactive Iodine Implants for the Treatment of Pan-invasive Pituitary Macroadenomas Recruiting NCT01444209 Phase 2
40 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors Recruiting NCT04042753 Phase 2 Ipilimumab;Nivolumab;Nivolumab
41 Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency Recruiting NCT04121780 Phase 2
42 Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC Active, not recruiting NCT02749227 Phase 2 Pasireotide LAR
43 Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas Active, not recruiting NCT03930771 Phase 2 Capecitabine;Temozolomide
44 A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas Not yet recruiting NCT04335357 Phase 2 TBR-760;Placebo
45 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
46 Pharmacodynamics and Safety of Human Recombinant Luteinising Hormone in Hypogonadotropic Hypogonadal Men Not yet recruiting NCT04189133 Phase 2 Lutropin alfa;Human chorionic gonadotropin
47 The Mission Connect Mild TBI Translational Research Consortium's Integrated Clinical Protocol Terminated NCT01013870 Phase 2 Atorvastatin;Placebo
48 An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
49 Rosiglitazone (Peroxisome Proliferating Activating Receptor-gamma {PPAR-y} Ligand) Treatment of Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
50 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab

Search NIH Clinical Center for Pituitary Gland Disease

Genetic Tests for Pituitary Gland Disease

Anatomical Context for Pituitary Gland Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Pituitary Gland Disease:

19
Pituitary Gland

MalaCards organs/tissues related to Pituitary Gland Disease:

40
Pituitary, Brain, Testes, Thyroid, Hypothalamus, Bone, Liver

Publications for Pituitary Gland Disease

Articles related to Pituitary Gland Disease:

(show top 50) (show all 1155)
# Title Authors PMID Year
1
Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. 42
32217809 2020
2
The Diagnostic Approach to the Patient with Hyponatremia: Are the Correct Investigations Being Done? 42
32097921 2019
3
Hyponatremia and Glucocorticoid Deficiency. 42
32097946 2019
4
Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. 61 54
17984238 2007
5
Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury. 54 61
17405254 2006
6
Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. 54 61
16882751 2006
7
[A case of primary hypothyroidism with pituitary enlargement and abnormal secretion of growth hormone and prolactin]. 54 61
7750626 1995
8
Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. 54 61
1479002 1992
9
Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. 61 54
2128941 1990
10
Central diabetes insipidus and pituitary stalk thickening in adults: distinction of neoplastic from non-neoplastic lesions. 61
32530258 2020
11
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity. 61
32383818 2020
12
Pre- and postoperative need for pituitary hormone replacement in non-adenomatous sellar and parasellar lesions: importance of the sellar encroachment score. 61
32506330 2020
13
Neuroendocrine function and associated mental health outcomes following mild traumatic brain injury in OEF-deployed service members. 61
32157738 2020
14
Adult craniopharyngioma: The role of extent of resection in tumor recurrence and long-term functional outcome. 61
32036264 2020
15
Traumatic brain injuries induced pituitary dysfunction: a call for algorithms. 61
32412425 2020
16
Axis-specific analysis and predictors of endocrine recovery and deficits for non-functioning pituitary adenomas undergoing endoscopic transsphenoidal surgery. 61
32388803 2020
17
Transient water-electrolyte disturbance after hemispherotomy in young infants with epileptic encephalopathy. 61
31845027 2020
18
Growth Hormone Alters Brain Morphometry, Connectivity, and Behavior in Subjects with Fatigue after Mild Traumatic Brain Injury. 61
31797721 2020
19
Diagnosis and treatment of autoimmune and IgG4-related hypophysitis: clinical guidelines of the Japan Endocrine Society. 61
32037390 2020
20
Lymphocytic Hypophysitis Presenting as Bilateral Abducens Nerve Palsy: A Case Report. 61
32395162 2020
21
Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. 61
32267349 2020
22
Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience. 61
31802354 2020
23
Primary central nervous system lymphoma involving the hypothalamic-pituitary axis: a case series and pooled analysis. 61
32221784 2020
24
Long-term neuroendocrine consequences of traumatic brain injury and strategies for management. 61
32133881 2020
25
The health status alters the pituitary function and reproduction of mice in a Cxcr2-dependent manner. 61
32041848 2020
26
A case of occult bilateral optic nerve aplasia with pituitary dysfunction: hidden anomaly missed on ultrasound. 61
32086325 2020
27
Pituitary dysfunction in granulomatosis with polyangiitis. 61
31446541 2020
28
Pituitary Dysfunction after Radiation for Anterior Skull Base Malignancies: Incidence and Screening. 61
32021753 2020
29
Epidemiology, natural history, and optimal management of neurohypophyseal germ cell tumors. 61
32032947 2020
30
Surgical management of clinically silent thyrotropin pituitary adenomas: A single center series of 20 patients. 61
31668712 2020
31
Orbitofrontal approach for the fenestration of a symptomatic sellar arachnoid cyst. 61
31966929 2020
32
Pituitary dysfunction in patients with ANCA associated vasculitis: prevalence, presentation, and outcomes. 61
32566116 2020
33
Clinical Characteristics of Pediatric Patients With Sellar and Suprasellar Lesions Who Initially Present With Central Diabetes Insipidus: A Retrospective Study of 55 Cases From a Large Pituitary Center in China. 61
32153511 2020
34
Pituitary apoplexy causing acute ischemic stroke: Which treatment should be given priority. 61
32494388 2020
35
Pituitary metastasis of lung adenocarcinoma: Case report and literature review. 61
32058309 2020
36
Prevalence of Anterior Pituitary Dysfunction Twelve Months or More following Traumatic Brain Injury in Adults: A Systematic Review and Meta-Analysis. 61
31111791 2020
37
Antibodies Against Hypothalamus and Pituitary Gland in Childhood-Onset Brain Tumors and Pituitary Dysfunction. 61
32132974 2020
38
Neoplastic metastases to the endocrine glands. 61
31645015 2020
39
A new imaging entity consistent with partial ectopic posterior pituitary gland: report of six cases. 61
31468085 2020
40
Role of apelin/APJ system in hypothalamic-pituitary axis. 61
31525345 2019
41
Thyroid Therapy or Dysfunction in Athletes: Is it Time to Revisit the Clinical Practice Guidelines? 61
31834179 2019
42
Craniopharyngioma in children: trends from a third consecutive single-center cohort study. 61
31860822 2019
43
Rehabilitation of anterior pituitary dysfunction combined with extrapontine myelinolysis: A case report. 61
31911927 2019
44
Clinicopathologic Characteristics and Endoscopic Surgical Outcomes of Symptomatic Rathke's Cleft Cysts. 61
31493602 2019
45
Neurosarcoidosis manifesting as panhypopituitarism. 61
31893082 2019
46
Cantu syndrome and hypopituitarism: implications for endocrine monitoring. 61
31743099 2019
47
Pituitary Dysfunction Among Men Presenting with Hypogonadism. 61
31734886 2019
48
Strategy and Technique of Endonasal Endoscopic Bony Decompression and Selective Tumor Removal in Symptomatic Skull Base Meningiomas of the Cavernous Sinus and Meckel's Cave. 61
31226453 2019
49
Methotrexate-associated lymphoproliferative disorder with hypopituitarism and central diabetes insipidus. 61
31610524 2019
50
Pituitary Apoplexy. 61
31471052 2019

Variations for Pituitary Gland Disease

Expression for Pituitary Gland Disease

Search GEO for disease gene expression data for Pituitary Gland Disease.

Pathways for Pituitary Gland Disease

Pathways related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 TRH SST PRL POMC GNRH1 GHRH
2
Show member pathways
12.6 POMC MEN1 INS CRH AIP
3
Show member pathways
11.88 POMC INS IGF1 GH1
4
Show member pathways
11.7 SST POU1F1 POMC IGF1 GHRH GH1
5 11.62 POMC GHRH CRH AVP
6 11.49 PRL POU1F1 POMC
7 10.43 PRL POMC INS
8 10.21 POMC CRH

GO Terms for Pituitary Gland Disease

Cellular components related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TRH SST PRL POMC INS IGF1
2 extracellular space GO:0005615 9.36 SST PRL POMC MIR93 INS IGF1
3 endosome lumen GO:0031904 9.13 PRL INS GH1

Biological processes related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 TRH PRL POMC INS IGF1 GNRH1
2 G protein-coupled receptor signaling pathway GO:0007186 9.97 TRH SST POMC INS GNRH1 GHRH
3 negative regulation of apoptotic process GO:0043066 9.93 PROP1 LHX3 IGF1 GNRH1 AVP
4 negative regulation of cell proliferation GO:0008285 9.89 SST POU1F1 MIR93 MEN1 GNRH1
5 cellular protein metabolic process GO:0044267 9.81 PRL MEN1 INS IGF1
6 positive regulation of cell proliferation GO:0008284 9.8 PRL POU1F1 INS IGF1 GHRH CRH
7 female pregnancy GO:0007565 9.72 PRL GNRH1 CRH
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 INS IGF1 GH1
9 positive regulation of multicellular organism growth GO:0040018 9.58 POU1F1 GHRH GH1
10 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.56 PRL GH1
11 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.5 IGF1 GHRH GH1
12 hormone-mediated apoptotic signaling pathway GO:0008628 9.46 SST CRH
13 somatotropin secreting cell differentiation GO:0060126 9.43 PROP1 POU1F1
14 adenohypophysis development GO:0021984 9.33 PROP1 POU1F1 GHRH
15 pituitary gland development GO:0021983 9.26 PROP1 POU1F1 LHX3 HESX1
16 cell-cell signaling GO:0007267 9.17 TRH SST POMC INS GNRH1 GHRH

Molecular functions related to Pituitary Gland Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.36 TRH SST PRL POMC INS IGF1
2 neuropeptide hormone activity GO:0005184 9.33 GHRH CRH AVP
3 insulin-like growth factor receptor binding GO:0005159 9.26 INS IGF1
4 prolactin receptor binding GO:0005148 8.96 PRL GH1

Sources for Pituitary Gland Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....